<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04657133</url>
  </required_header>
  <id_info>
    <org_study_id>RICH-2</org_study_id>
    <nct_id>NCT04657133</nct_id>
  </id_info>
  <brief_title>Remote Ischemic Conditioning for the Treatment of Intracerebral Hemorrhage</brief_title>
  <acronym>RICH-2</acronym>
  <official_title>The Safety and Efficacy of Remote Ischemic Conditioning for the Treatment of Intracerebral Hemorrhage: A Multicenter, Randomized, Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intracerebral hemorrhage (ICH) results from the rupture of small vessels damaged by chronic&#xD;
      hypertension, amyloid angiopathy or other disease. Currently, ICH has been a devastating type&#xD;
      of stroke that lacking effective therapy. Remote ischemic conditioning (RIC), a&#xD;
      systematically protective strategy, has been found to have neuroprotective effects by in&#xD;
      patients with ischemic stroke. In addition, animal studies show that RIC is safe in ICH model&#xD;
      and it could accelerate the absorption of hematoma. In a previous clinical study (RICH-1),&#xD;
      RIC have been found to be safe and well-tolerated in patients with ICH. Therefore, the&#xD;
      investigators plan to undertake this study to further evaluate the safety and efficacy of RIC&#xD;
      in patients with ICH.&#xD;
&#xD;
      The investigators hypothesize that treatment with RIC will accelerate the absorption of&#xD;
      hematoma and improve patients' functional outcomes. Results of this study can potentially&#xD;
      bring into account new means to improve the outcomes of ICH patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients With Modified Rankin Scale (mRS) Score 0-2 at 90 Days</measure>
    <time_frame>0-90 days.</time_frame>
    <description>The mRS ranges from 0 to 6, with higher scores indicating worse outcome. The primary outcome measure is the mRS score, dichotomized to define favorable functional outcome as mRS 0-2 at 90 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With mRS Score 0-3 at 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>The mRS ranges from 0 to 6, with higher scores indicating worse outcome. Another measure of efficacy is the mRS score, dichotomized to define good functional outcome as mRS 0-3 at 90 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With mRS Score 0-2 at 180 Days</measure>
    <time_frame>180 days</time_frame>
    <description>The mRS ranges from 0 to 6, with higher scores indicating worse outcome. Another measure of efficacy is the mRS score, dichotomized to define good functional outcome as mRS 0-2 at 180 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With mRS Score 0-3 at 180 Days</measure>
    <time_frame>180 days</time_frame>
    <description>The mRS ranges from 0 to 6, with higher scores indicating worse outcome. Another measure of efficacy is the mRS score, dichotomized to define good functional outcome as mRS 0-3 at 180 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Experiencing Serious Adverse Events</measure>
    <time_frame>90 days</time_frame>
    <description>Number of subjects experiencing Serious adverse events at any time from randomization through day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events Within 7 Days</measure>
    <time_frame>7 days</time_frame>
    <description>Number of Subjects Experiencing Serious Adverse Events within 7 days of randomization</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes of intracerebral hematoma volume</measure>
    <time_frame>0-7 days after enrollment.</time_frame>
    <description>Intracerebral hematoma volume (ml) is assessed by CT brain scan</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes of perihematomal edema volume</measure>
    <time_frame>0-7 days after enrollment.</time_frame>
    <description>Perihematomal edema volume (ml) is assessed by CT brain scan</description>
  </other_outcome>
  <other_outcome>
    <measure>Ordinal Distribution of Scores on mRS at Day 90</measure>
    <time_frame>90 days</time_frame>
    <description>The overall ordinal distribution of scores on mRS at 90 days in all subjects of two groups will be determined.</description>
  </other_outcome>
  <other_outcome>
    <measure>Ordinal Distribution of Scores on mRS at Day 180</measure>
    <time_frame>180 days</time_frame>
    <description>The overall ordinal distribution of scores on mRS at 180 days in all subjects of two groups will be determined.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">452</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <condition>Acute Stroke</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the intervention group will receive remote ischemic conditioning and standard background medical treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in the placebo group will receive sham remote ischemic conditioning and standard background medical treatment alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Remote ischemic conditioning</intervention_name>
    <description>RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 7 days after enrollment.</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>RIC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham remote ischemic conditioning</intervention_name>
    <description>Sham RIC will be performed by the same electric autocontrol device with cuff placed on arm. Sham RIC procedures consist of five cycles of 5-min inflation (30 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 7 days after enrollment.</description>
    <arm_group_label>Sham group</arm_group_label>
    <other_name>Sham RIC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard medication therapy</intervention_name>
    <description>Standard medication therapy will be performed according to the national and international guidelines.</description>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_label>Sham group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 and ≤ 80 years&#xD;
&#xD;
          2. The diagnosis of supratentorial ICH is confirmed by brain CT scan&#xD;
&#xD;
          3. Hematoma volume of 10 to 30 ml and Glasgow Coma Score (GCS)&gt;8 at randomization.&#xD;
&#xD;
          4. National Institutes of Health Stroke Scale (NIHSS)≥6 and ≤20 points at randomization.&#xD;
&#xD;
          5. Randomization and starting treatment between 24 and 48 hours of symptom ictus.&#xD;
&#xD;
          6. Signed and dated informed consent is obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Planned surgical evacuation of ICH prior to administration of investigational&#xD;
             intervention&#xD;
&#xD;
          2. ICH concomitant with subarachnoid hemorrhage or intraventricular hemorrhage&#xD;
&#xD;
          3. Suspected secondary ICH related to tumor, ruptured aneurysm or arteriovenous&#xD;
             malformation, hemorrhagic transformation of an ischemic infarct, or venous sinus&#xD;
             thrombosis&#xD;
&#xD;
          4. Patients with a pre-existing neurological deficit (mRS&gt;1) or psychiatric disease that&#xD;
             would confound the neurological or functional evaluations.&#xD;
&#xD;
          5. Coagulopathy - defined as elevated aPTT or INR &gt;1.3 upon presentation; concurrent use&#xD;
             of direct thrombin inhibitors (such as dabigatran), direct factor Xa inhibitors (such&#xD;
             as rivaroxaban or apixaban), or low-molecular-weight heparin&#xD;
&#xD;
          6. Severe renal disease (i.e., renal disorder requiring dialysis ) or eGFR&#xD;
             &lt;30ml/min/1.73m2&#xD;
&#xD;
          7. Severe liver disorder, or ALT &gt;3 times or bilirubin &gt;2 times upper limit of normal&#xD;
&#xD;
          8. Known severe hearing loss or cognitive impairment&#xD;
&#xD;
          9. Known pregnancy, or positive pregnancy test, or breastfeeding&#xD;
&#xD;
         10. Patients known or suspected of not being able to comply with the study protocol due to&#xD;
             alcoholism, noncompliance or any other cause&#xD;
&#xD;
         11. Life expectancy of less than 90 days due to co-morbid conditions&#xD;
&#xD;
         12. Concurrent participation in another research protocol for investigation of another&#xD;
             experimental therapy&#xD;
&#xD;
         13. Severe, sustained hypertension (Systolic blood pressure&gt; 180 mmHg or diastolic blood&#xD;
             pressure&gt; 110 mmHg).&#xD;
&#xD;
         14. Contraindication for remote ischemic conditioning: severe soft tissue injury,&#xD;
             fracture, or peripheral vascular disease in the upper limbs.&#xD;
&#xD;
         15. Any condition which, in the judgement of the investigator, might increase the risk to&#xD;
             the patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xunming Ji, MD, PhD</last_name>
    <phone>010-83199430</phone>
    <email>jixm@ccmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenbo Zhao, MD, PhD</last_name>
    <phone>86-13120136877</phone>
    <email>zhaowb@xwh.ccmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xuanwu Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Red Cross Emergency Rescue Center</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Renhe Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijng</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Na Li, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Qiqihar</name>
      <address>
        <city>Qiqihar</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chenghe Sun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongliao Municipal Hosptial</name>
      <address>
        <city>Tongliao</city>
        <state>Inner Mongolia Autonomous Region</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yaoming Xu, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Changzhou</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Song Yang, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiaxing Second Hospital</name>
      <address>
        <city>Jiaxing</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianguo Shen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhuji People's Hospital of Zhejaing Province</name>
      <address>
        <city>Zhuji</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Shoamanesh A, Patrice Lindsay M, Castellucci LA, Cayley A, Crowther M, de Wit K, English SW, Hoosein S, Huynh T, Kelly M, O'Kelly CJ, Teitelbaum J, Yip S, Dowlatshahi D, Smith EE, Foley N, Pikula A, Mountain A, Gubitz G, Gioia LC. Canadian stroke best practice recommendations: Management of Spontaneous Intracerebral Hemorrhage, 7th Edition Update 2020. Int J Stroke. 2021 Apr;16(3):321-341. doi: 10.1177/1747493020968424. Epub 2020 Nov 11.</citation>
    <PMID>33174815</PMID>
  </reference>
  <reference>
    <citation>Hemphill JC 3rd, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, Fung GL, Goldstein JN, Macdonald RL, Mitchell PH, Scott PA, Selim MH, Woo D; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015 Jul;46(7):2032-60. doi: 10.1161/STR.0000000000000069. Epub 2015 May 28.</citation>
    <PMID>26022637</PMID>
  </reference>
  <reference>
    <citation>Zhao W, Jiang F, Li S, Liu G, Wu C, Wang Y, Ren C, Zhang J, Gu F, Zhang Q, Gao X, Gao Z, Song H, Ma Q, Ding Y, Ji X; RICH-1 Investigators. Safety and efficacy of remote ischemic conditioning for the treatment of intracerebral hemorrhage: A proof-of-concept randomized controlled trial. Int J Stroke. 2021 Apr 7:17474930211006580. doi: 10.1177/17474930211006580. [Epub ahead of print]</citation>
    <PMID>33739197</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Ji Xunming,MD,PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Therapy</keyword>
  <keyword>Neuroprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

